Abstract: A process of preparing a nitroalcohol, e.g., 2-nitro-2-methyl-1-propane, from a nitropolyol, e.g., 2-nitro-2-methyl-1,3-propanediol, the process comprising the step of contacting under hydrogenation conditions the nitropolyol with hydrogen, a hydrogenation catalyst and, optionally, a chelating agent.

Abstract: Process for preparing a macromonomer, in which a starting compound H2C?CR1—C6H4-s(R4)s—R3—OH or H2C?CR2—CO—NH—R3—OH, where R1 and R2 are each H or a linear or branched alkyl radical having from 1 to 4 carbon atoms, R3 is a linear or branched alkylene, aralkylene radical which has from 1 to 20 carbon atoms and can contain one or more hydroxy groups and the radicals R4 are each, independently of one another, a linear or branched alkyl, aralkyl, alkoxy or aralkoxy radical having from 1 to 20 carbon atoms and s=0-4, is, after partial deprotonation, reacted with at least one hydroxy-functional oxirane compound in the presence of an inhibitor of free-radical polymerization with opening of the oxirane ring, where the molar ratio of the molar amounts used n(starting compound):n(oxirane compound) is in the range from 1:100 to 1:1. Macromonomers which can be obtained by the process, polymers which can be obtained therefrom and their use as additives in coating compositions, plastics and cosmetics.

Abstract: The present invention, which enables to align a liquid crystal molecule, when no voltage is applied thereto, and also to control pretilt angle of the liquid crystal molecule, relates to a composition for a liquid crystal alignment film comprising components represented by the following (A) to (D): (A) a meta-phenylene diamine derivative represented by the general formula [1]; (B) a meta-phenylene diamine derivative represented by the general formula [2]; (C) a para-arylene diamine represented by the general formula [3]; (D) a tetracarboxylic acid represented by the general formula [4] or a tetracarboxylic acid anhydride represented by the general formula [4?]; (wherein R1 represents an alkyl group having 1 to 6 carbon atoms or the like, R2 represents an alkyl group having 8 to 20 carbon atoms or the like, t moieties of Ra represent an alkyl group having 1 to 3 carbon atoms or the like, n represents an integer of 1 to 3, t represents an integer of 0 to 4, T represents an oxygen atom or the like, Y repre

Abstract: A process of preparing a nitroalcohol, e.g., 2-nitro-2-methyl-1-propane, from a nitropolyol, e.g., 2-nitro-2 -methyl-1,3-propanediol, the process comprising the step of contacting under hydrogenation conditions the nitropolyol with hydrogen, a hydrogenation catalyst and, optionally, a chelating agent.

Abstract: A process for making a 2-nitro-1-ethanol derivative of formula III: wherein R3 is as described herein is provided. Novel 2-nitro-1-ethanol derivatives provided.

Abstract: The present disclosure is generally directed to neuroactive substituted cyclopenta[b]phenanthrenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Abstract: A process for making a tertiary aminoalcohol compound is disclosed. The process comprises using an excess amount of a carbonyl compound in a condensation step between the carbonyl compound and a nitroalkane in the presence of a catalytic amount of a tertiary aminoalcohol compound, and conducting a hydrogenation/alkylation step to produce the tertiary aminoalcohol. The tertiary aminoalcohol compound used to catalyze the condensation step is preferably the same tertiary aminoalcohol compound produced in the hydrogenation/alkylation step. The process uses fewer steps than conventional processes.

Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

Abstract: The invention relates to a process for making HOF.RCN and using it to oxidise organic substrates in a quick and safe way. The process comprises passing diluted fluorine through a conduit and RCN in water through another conduit into a microreactor to form HOF.RCN and reacting this with an organic substrates.

Abstract: The present invention relates to the preparation of highly efficient chiral heterogeneous catalyst for asymmetric nitroaldol reaction, wherein Henry reactions of various aldehydes such as aromatic, aliphatic, ?,?-unsaturated aldehydes, alicyclic aldehydes and nitroalkenes were carried out to produce optically active ?-nitroalcohols in high yield, with moderate to excellent enantioselectivity (ee up to >99%) in presence of a base and an optically active chiral heterogeneous catalyst.

Abstract: Provided is a process for the formation of 2-nitropropane and/or 2,2-dinitropropane by the nitration of propane with dilute nitric acid.

Abstract: Provided herein are chiral triazolium catalysts useful for asymmetric C—C bond formation and processes for their preparation. Also provided are synthetic reactions in which these catalysts are used, in particular, in asymmetric C—C bond formation.

Abstract: New polymeric quaternary ammonium compounds with vicinal hydroxyl groups are disclosed. These compounds are useful as disinfectants in contact lens care compositions and/or as preservatives in ophthalmic compositions. Compositions containing these compounds are also disclosed. These compositions are especially useful for disinfecting/cleaning contact lenses.

Abstract: The present invention relates to the preparation of highly efficient chiral heterogeneous catalyst for asymmetric nitroaldol reaction, wherein Henry reactions of various aldehydes such as aromatic, aliphatic, ?,?-unsaturated aldehydes, alicyclic aldehydes and nitroalkenes were carried out to produce optically active ?-nitroalcohols in high yield, with moderate to excellent enantioselectivity (ee up to >99%) in presence of a base and an optically active chiral heterogeneous catalyst.

Abstract: Nitroaldol (“Henry”) reactions between nitroalkanes and aldehydes in the presence of a catalyst and a two-phase reaction medium produce nitroalcohols at increased reaction rates compared to single-phase organic solvent systems, and do not require use of surfactants as is typical of single-phase aqueous solvent systems and solventless systems. The reaction medium comprises an organic solvent phase and an aqueous solvent phase. The aqueous solvent may be 100% water.

Abstract: The invention provides novel compounds and methods to carry out organocatalytic Michael additions of aldehydes to nitroethylene catalyzed by a proline derivative to provide ?-substituted-?-nitroaldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96-99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to protected ?2-amino acids, which are essential for systematic conformational studies of ?-peptide foldamers.

Abstract: The present invention relates to a covalently organo-modified LDH (LDH/APTES) was found to be an efficient and reusable heterogeneous catalyst for C-C bond forming reactions (i.e. Aldol condensation, Knoevenagel condensation, Henry reaction, Michael addition). More particularly, this catalyst shows consistent activity for several cycles in C-C bond forming reaction. These catalysts were successfully characterized by XRD, FT-IR, 29Si CP MAS NMR.

Abstract: Nitroaldol (“Henry”) reactions between nitroalkanes and aldehydes in the presence of a catalyst and a two-phase reaction medium produce nitroalcohols at increased reaction rates compared to single-phase organic solvent systems, and do not require use of surfactants as is typical of single-phase aqueous solvent systems and solventless systems. The reaction medium comprises an organic solvent phase and an aqueous solvent phase. The aqueous solvent may be 100% water.

Abstract: A process for the preparation of a polyol which includes reacting an amino-group-containing starter compound with an alkylene oxide in the presence of a catalyst to form a polyol, wherein the catalyst is based on a compound selected from the group consisting of alkali metal hydroxides, alkali, alkaline earth metal hydrides, alkaline earth metal carboxylates, and alkaline earth hydroxides, and wherein the catalyst is present in an amount of from 0.004 to 0.1 wt. % based on the amount of polyol; and neutralizing the polyol with from 0.75 to 1 mol of sulfuric acid per mol of catalyst used.

Abstract: The invention relates to a process for making HOF.RCN and using it to oxidise organic substrates in a quick and safe way. The process comprises passing diluted fluorine through a conduit and RCN in water through another conduit into a microreactor to form HOF.RCN and reacting this with an organic substrates.

Abstract: Provided is a process for the formation of 2-nitropropane and/or 2,2-dinitropropane by the nitration of propane with dilute nitric acid.

Abstract: Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

Abstract: The present invention provides porous body precursors and shaped porous bodies. Also included are catalysts and other end-use products based upon the shaped porous bodies and thus the porous body precursors. Finally, processes for making these are provided. The porous body precursors are germanium doped and comprise a precursor alumina blend. It has now surprisingly been discovered that inclusion of germanium, alone or in combination with such a blend, in porous body precursors can provide control over, or improvements to, surface morphology, physical properties, and/or surface chemistry of shaped porous bodies based thereupon. Surprisingly and advantageously, heat treating the shaped porous bodies can result in additional morphological changes so that additional fine tuning of the shaped porous bodies is possible in subsequent steps.

Abstract: The present invention provides rhenium-promoted epoxidation catalysts based upon shaped porous bodies comprising a minimized percentage of their total pore volume being present in pores having diameters of less than one micron, and a surface area of at least about 1.0 m2/g. Processes of making the catalysts and using them in epoxidation processes are also provided.

Abstract: The present invention relates to a process for the preparation of 1,4-butanediol mononitrate as intermediate for large scale preparation of high purity nitrooxybutyl ester of pharmaceutically active compounds.

Abstract: Disclosed is a process for preparing 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide hydrochloride, an intermediate useful in the preparation of the HCV protease inhibitor (1R,5S)—N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide.

Abstract: A polymer that contains an antimicrobial, bioresistant and fungal resistant moiety that is linked into the backbone of the polymer. The moiety is a bromine atom and a nitro group linked to one or more of the carbon atoms forming the backbone. The moiety can appear in the polymer chain in various levels of occurrence from 5 ppm to has high as 100% with a normal occurrence of between 1000 ppm to 20,000 ppm. Polymer types that can be created with this moiety to display these properties include, but are not limited to, polyurethane, polyurea, polyamide, polyester, polycarbonate, polyether, polysiloxane, epoxy, polyacrylic, polyacrylate, polyvinyl.

Abstract: A polyol monomer comprising the formula: R1 and R3 are —H, aliphatic, aromatic, or ether; R2 is aliphatic, aromatic, ester, ether, or acrylic, and R1 contains a hydroxyl group, R3 contains a hydroxyl group, R2 contains —O—CH2—CH(OH)—, or any combination thereof. The polyol monomer may be made by reacting an epoxy and an amine. Either the epoxy contains more than one epoxide groups, the amine contains a hydroxyl group, or both. A thermoset made by reacting the polyol monomer with a polyisocyanate.

Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.

Abstract: The present invention provides compounds and methods that can be used to convert the intermmediate halomethyl ketones (HMKs), e.g., chloromethyl ketones, to the corresponding S,S- and R,S-diastereomers. More particularly, the present invention provides: (1) reduction methods; (2) inversion methods; and (3) methods involving the epoxidation of alkenes. Using the various methods of the present invention, the R,S-epoxide and the intermediary compounds can be prepared reliably, in high yields and in high purity.

Abstract: An activated, substantially water soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated poly(ethylene glycol) and the biologically active agent.

Abstract: Process for the preparation of enantiomerically enriched amino aldehydes and amino alcohols, wherein a corresponding enantiomerically enriched amino nitrile is subjected to hydrogenation in the presence of hydrogen, a hydrogenation catalyst, preferably a Pd-catalyst and a mineral acid. For the preparation of an amino aldehyde hydrogen preferably is present at a hydrogen-pressure between 0.1 and 2 MPa, in particular between 0.5 and 1 MPa. The amino aldehyde preferably is isolated in the form of a chemically and configurationally stable derivative. For the preparation of an amino alcohol, preferably at least during part of the hydrogenation hydrogen is present at a hydrogen-pressure between 2 and 10 MPa, in particular between 4 and 6 MPa. In a preferred embodiment the hydrogen-pressure initially is between 0.5 and 2 MPa and subsequently, after most of the nitrile starting material is converted, the hydrogen pressure is increased to a value between 2 and 10 MPa.

Abstract: An activated, substantially water soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated poly(ethylene glycol) and the biologically active agent.

Abstract: There is disclosed an optically active salicylideneaminoalcohol compound of formula (1): wherein R1 represents an alkyl group or the like, R2 represents an aryl group and the like, and when X1 represents a nitro, X2 is a hydrogen atom, when X1 represents a chlorine atom, X2 is a chlorine atom, and when X1 is a hydrogen atom, X2 is a fluorine atom; and the carbon atom denoted by “*” is an asymmetric carbon atom having either an S or R configuration, and a chiral copper complex produced from the optically active salicylidenaminoalcohol compound and a copper compound.

Abstract: The present invention relates to a process for producing optically active ?-nitroalcohols wherein nitroaldol reactions of aldehydes and nitroalkanes are carried out in the presence of a base and an optically active metal complex catalyst represented by the following formula (c): (where R4, R5, and R6 represent a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, an acyl group, an alkoxycarbonyl group, or an aryloxycarbonyl group, and R5 and R6 may be linked together to form a ring; X* represents a hydrocarbon group having an asymmetric carbon atom or axial asymmetry; M represents a cobalt ion or a chromium ion; and Y represents an anion capable of forming a salt when the valence of M is larger than that of a ligand).

Abstract: The invention relates, as novel and useful industrial products, to triaromatic compounds, which are vitamin D analogues, of general formula (I): and also to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Abstract: Disclosed are multibinding compounds which are ?2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: The invention relates to 5-amino-1-pentene-3-ol substituted derivatives, a method for the production thereof, medicaments containing said compounds, the use of substituted 5-amino-1-pentene-3-ol derivatives for the production of medicaments, and methods of treatment using the medicaments.

Abstract: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: There is disclosed an optically active salicylideneaminoalcohol compound of formula (1): wherein R1 represents an alkyl group or the like, R2 represents an aryl group and the like, and when X1 represents a nitro, X2 is a hydrogen atom, when X1 represents a chlorine atom, X2 is a chlorine atom, and when X1 is a hydrogen atom, X2 is a fluorine atom; and the carbon atom denoted by “*” is an asymmetric carbon atom having either an S or R configuration, and a chiral copper complex produced from the optically active salicylidenaminoalcohol compound and a copper compound.

Abstract: This invention relates to a process for the preparation an epoxide-reactive compound having a functionality of at least 3, a molecular weight of from about 250 to about 1,900, and an OH number of from about 85 to about 1,400. This process comprises reacting (a) an organic compound which is free of ether groups, having a molecular weight of from about 60 to about 600, and containing from about 2 to about 8 reactive sites; with (b) cyanuric chloride; optionally, in the presence of (c) one or more catalysts; wherein the functionality of the resultant epoxide-reactive compound equals three times the functionality of (a) said organic compound minus three. This invention also relates to further reacting the epoxide-reactive compound produced by the above process with an alkylene oxide, optionally in the presence of a catalyst to form a polyether polyol having a functionality of at least about 3, a molecular weight of from about 300 to about 18,000, and an OH number of from about 10 to about 565.

Abstract: This invention relates to a process for the preparation of a polyether polyol having a functionality of at least about 3, a molecular weight of from about 560 to about 35,000 and an OH number of from about 10 to about 1,100. This process comprises reacting (a) a polyether polyol containing one or more ether groups, having a functionality of about 2 to about 8, a molecular weight of about 106 to about 12,000, and an OH number of about 28 to about 1,400, with (b) cyanuric chloride, optionally, in the presence of (c) one or more catalysts; wherein the functionality of the resultant polyether polyols equals three times the functionality of (a) said polyether polyol, minus three.

Abstract: A water-soluble polyurethane obtained from water-soluble polyalkylene glycol, polydiisocyanate, and comb-shaped hydrophobic diol represented by the following general formula: wherein R1 is a hydrocarbon group of 1 to 20 carbon atoms; each of R2 and R3 is a hydrocarbon group or halogenated hydrocarbon group of 4 to 21 carbon atoms; each of X, X′ and X″ is an alkylene group of 2 to 10 carbon atoms; the hydrogen atoms of the above alkylene group may be substituted with an alkyl group, chlorine or an alkyl chloride group; each of Z and Z′ is oxygen, sulfur or a CH2 group; R4 is an alkylene group of 2 to 10 carbon atoms in all; k is an integer of 0 to 15; n is an integer of 0 to 15 when Z is oxygen and is 0 when Z is sulfur or a CH2 group; n′ is an integer of 0 to 15 when Z′ is oxygen and is 0 when Z′ is sulfur or a CH2 group.

Abstract: An activated, substantially water soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated poly(ethylene glycol) and the biologically active agent.

Abstract: An aqueous phase inhibitor for quenching free radical polymerization comprising a free radical quenching agent having a hydrophilic tail is disclosed, as well as a coating and related methods. In one embodiment, the free radical quenching agent can either be an N-hydroxylamine or an N-nitrosonamine, the hydrophilic tail can be a polyhydric alcohol tail and the inhibitor can be a concentrate in a liquid medium such as water, alcohol and mixture thereof.

Abstract: There is disclosed an optically active salicylideneaminoalcohol compound of formula (1): 1

Abstract: The present invention has its objects to provide a method for reducing &agr;-aminoketone derivatives under mild conditions with high stereoselectivity.

Abstract: In a process for preparing polyether polyols containing aromatics by molecular addition of alkylene oxides to H-functional initiators at from 70.degree. C. to 135.degree. C. and pressures of from 0.1 MPa to 1.0 MPa, the alkoxylation is carried out using at least one initiator comprising at least 95% by weight of 2,3 and 3,4 isomers of tolylenediamine, from 0.5 to 4% by weight of 2,4 and 2,6 isomers of tolylenediamine and from 0.1 to 1.5% by weight of more volatile fractions from tolylenediamine production. The polyether polyols prepared by this process can be used as component of a polyol mixture for producing rigid polyurethane foams.

Abstract: Enzymatically cleavable chemiluminescent 1,2-dioxetane compounds capable of producing light energy when decomposed, substantially stable at room temperature before a bond by which an enzymatically cleavable labile substituent thereof is intentionally cleaved, are disclosed. These compounds can be represented by the formula: ##STR1## wherein: X and X.sup.1 each represent, individually, hydrogen, a hydroxyl group, a halo substituent, an unsubstituted lower alkyl group, a hydroxy (lower) alkyl group, a halo (lower) alkyl group, a phenyl group, a halophenyl group, an alkoxyphenyl group, a hydroxyalkoxy group, a cyano group or an amide group, with at least one of X and X.sup.1 being other than hydrogen; andR.sub.1 and R.sub.2, individually or together, represent an organic substituent that does not interfere with the production of light when the dioxetane compound is enzymatically cleaved and that satisfies the valence of the dioxetane compound's 4-carbon atom, with the provisos that if R.sup.1 and R.sub.

Abstract: Novel substrates of phospholipases, lysophospholipases and lipases are disclosed.